(Q34391968)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Pushpendra Singh

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jimi Marin Alex

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

14 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

805

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12032-013-0805-3

3 March 2020

exact match

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Risk of endometrial and breast cancer in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Diabetes mellitus and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Diabetes mellitus and risk of prostate cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Diabetes: risk factor for the development of pancreatic cancer or manifestation of the disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The relation of type 2 diabetes and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Adiponectin as a biomarker of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factors and neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The therapeutic potential of agents targeting the type I insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-Like Growth Factor (IGF) family and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Altered expression of insulin receptor isoforms in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Biology of insulin-like growth factors in development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin mediates glucose-stimulated phosphorylation of PHAS-I by pancreatic beta cells. An insulin-receptor mechanism for autoregulation of protein synthesis by translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Disrupting insulin-like growth factor signaling as a potential cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Structural biology of insulin and IGF1 receptors: implications for drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The insulin-like growth factor system and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The insulin-like growth factor-binding protein (IGFBP) superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factor binding proteins in the human circulation: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Significant expression of IGFBP2 in breast cancer compared with benign lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The IGF system in thyroid cancer: new concepts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin receptor expression by human prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Molecular interactions of the IGF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Regulating insulin-receptor-gene expression by differentiation and hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Tyrphostins and other tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Tyrphostins. II. Heterocyclic and .alpha.-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factor: current concepts and new developments in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factor receptor I targeting in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Di-diabody: a novel tetravalent bispecific antibody molecule by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Recombinant bispecific antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

The insulin-like growth factor 1 receptor in cancer: old focus, new future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Agonism and antagonism at the insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

A novel high-affinity peptide antagonist to the insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

S961, an insulin receptor antagonist causes hyperinsulinemia, insulin-resistance and depletion of energy stores in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0805-3

Obesity, metabolic syndrome, and prostate cancer

21 January 2018

1 reference

12 December 2020

Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo

1 reference

12 December 2020

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

1 reference

12 December 2020

The insulin and insulin-like growth factor receptor family in neoplasia: an update

1 reference

12 December 2020

The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells

1 reference

12 December 2020

1 reference

12 December 2020

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

1 reference

12 December 2020

Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches.

1 reference

12 December 2020

IGF-IR and its inhibitors in gastrointestinal carcinomas (Review).

1 reference

12 December 2020

Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis

1 reference

12 December 2020

Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies

1 reference

12 December 2020

The role of insulin receptors and IGF-I receptors in cancer and other diseases

1 reference

12 December 2020

Insulin-like growth factors and prostate cancer

1 reference

12 December 2020

Mechanisms of antibody-mediated insulin-like growth factor I receptor (IGF-IR) down-regulation in MCF-7 breast cancer cells.

1 reference

12 December 2020

Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis

1 reference

12 December 2020

A meta-analysis of diabetes mellitus and the risk of prostate cancer

1 reference

12 December 2020

1 reference

12 December 2020

Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling

1 reference

12 December 2020

An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation

1 reference

12 December 2020

1 reference

12 December 2020

A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.

1 reference

12 December 2020

Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling

1 reference

12 December 2020

Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes.

1 reference

12 December 2020

Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications

1 reference

12 December 2020

10.1007/S12032-013-0805-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 March 2020

1021000358

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338270%20AND%20SRC:MED&resulttype=core&format=json